Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom

Journal of the American Medical Association

Volumn 284, Issue 18, 2000, Pages 2334-2340

  Heath, Paul T ^a,f   Booy, Robert ^c   Azzopardi, Helen J ^b   Slack, Mary P E ^b   Bowen Morris, Jane ^a   Griffiths, Helen ^a   Ramsay, Mary E ^b   Deeks, Jon J ^f   Moxon, E Richard ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f Institute of Health Sciences ^*

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED KINGDOM; VACCINATION;

EID: 0034623658     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.284.18.2334     Document Type: Article

References (38)

1. Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age
2. A comparative study of PENTA (TM) vaccine booster doses given at 12, 15 or 18 months of age
3. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b
4. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease
5. Ten years experience with Haemophilus influenzae type b (Hib) conjugate vaccines in Finland
6. Immunisation against Haemophilus influenzae type b in Iceland: Results after 6 years of PRP-D (ProHIBiT)
7. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine
8. PCR for capsular typing of Haemophilus influenzae
9. Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule
10. Antibody persistence after accelerated immunisation against Haemophilus influenzae type b
11. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T
12. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T
13. Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91)
14. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster
15. Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme
16. Progress toward eliminating Haemophilus influenzae type b disease among infants and children - United States, 1987-1997
17. Mathematical models of Haemophilus influenzae type b
18. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine
19. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines
20. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska
21. Immunological response to conjugate vaccines in infants: Follow up study
22. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization
23. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanuspertussis containing acellular pertussis
24. Clinical and immunological factors associated with Hib conjugate vaccine failure in childhood
25. Recent trends in pediatric Haemophilus influenzae type B infections in Canada. Immunization Monitoring Program, Active (IMPACT) of the Canadian Paediatric Society and the Laboratory Centre for Disease Control
26. Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: High efficacy and lack of herd immunity
27. The decline of Haemophilus influenzae type b disease in Australia
28. Perspective: A five-country analysis of the impact of four different haemophilus influenzae type b conjugates and vaccination strategies in scandinavia
29. The Gambian Haemophilus influenzae type b vaccine trial: What does it tell us about the burden of Haemophilus influenzae type b disease?
30. Getting Hib vaccine to those who need it
31. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: Practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections
32. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants
33. Haemophilus influenzae type b meningitis in The Gambia after introduction of a conjugate vaccine
34. Economisation of vaccination against Haemophilus influenzae type b: A randomised trial of immunogenicity of fractional-dose and two-dose regimens